Concord Biotech Limited vs Glenmark Pharmaceuticals Limited
Last updated: 22 October 2026
Concord Biotech vs Glenmark Pharmaceuticals: A MoneyDock Comparison
In the dynamic Indian pharmaceutical landscape, investors often seek opportunities across various segments. Today, we put two distinct players under the microscope: Concord Biotech Limited and Glenmark Pharmaceuticals Limited. While both operate within the broader healthcare sector, they cater to different niches. Concord Biotech is known for its biopharmaceutical products, particularly focusing on fermentation-based APIs (Active Pharmaceutical Ingredients) and formulations. Glenmark Pharmaceuticals, on the other hand, is a global pharmaceutical company with a presence in generics, specialty, and OTC (Over-The-Counter) products, boasting a diverse portfolio of therapeutic areas. This comparison aims to provide MoneyDock readers with a clearer picture of their current market standing based on key financial metrics.
Key Financial Metrics Comparison
| Metric | Concord Biotech Limited | Glenmark Pharmaceuticals Limited |
|---|---|---|
| Current Price | ₹1270.70 | ₹2198.50 |
| 52W High | ₹1579.40 | ₹2515.00 |
| 52W Low | ₹1014.80 | ₹1920.40 |
| 1-Year Return | -7.88% | 11.80% |
| Trailing P/E | N/A | N/A |
| Market Cap | N/A | N/A |
Analysis: Who Wins?
Based on the provided numbers, we can draw some initial conclusions across various aspects:
Valuation: Unfortunately, with both companies showing 'N/A' for Trailing P/E and Market Cap, a direct comparison on traditional valuation metrics is not possible from the given data. Investors would need to delve deeper into other financial statements to assess their relative valuations.
Returns: On the one-year return front, Glenmark Pharmaceuticals clearly outperforms Concord Biotech. Glenmark has delivered a positive return of 11.80%, indicating stronger investor confidence and potentially better performance over the past year. In contrast, Concord Biotech has seen a negative return of -7.88%, suggesting a period of underperformance or correction.
Stability & Price Action: Looking at the 52-week price range, Glenmark Pharmaceuticals' current price of ₹2198.50 is closer to its 52-week high of ₹2515.00 than its low of ₹1920.40. This suggests relatively stable or upward momentum. Concord Biotech, with a current price of ₹1270.70, is also positioned above its 52-week low of ₹1014.80, but its 52-week high was ₹1579.40, indicating it has fallen more significantly from its peak compared to Glenmark, aligning with its negative one-year return.
Overall, based purely on the provided performance metrics, Glenmark Pharmaceuticals demonstrates stronger recent performance and price stability compared to Concord Biotech.
MoneyDock Verdict
For Aggressive Investors: Glenmark Pharmaceuticals might be more appealing given its positive 1-year return of 11.80% and current price being closer to its 52-week high, suggesting better momentum. However, aggressive investors might also see Concord Biotech's -7.88% return as a potential 'buy on dip' opportunity if they believe in its long-term growth story, assuming deeper fundamental analysis supports this.
For Conservative Investors: Glenmark Pharmaceuticals appears to be the safer bet of the two based on the provided data, due to its positive and more stable one-year performance. Concord Biotech's negative return could signal higher risk for those prioritizing capital preservation.
For Long-Term SIP Investors: Without P/E or Market Cap data, and a longer historical performance view, it's challenging to make a definitive long-term SIP recommendation. However, Glenmark's positive recent performance suggests a more favorable entry point and consistent performance for a SIP strategy compared to Concord Biotech's current dip. For long-term investors, further research into growth prospects, management quality, and competitive advantages beyond these limited metrics is crucial for both companies.
Price data from Yahoo Finance. AI analysis by MoneyDock. Not financial advice — always do your own research before investing.